Bookmark and Share

Compound Summary for: CID 5743186


Also known as: UNII-E367I8C7FI; GW64085X; Brecanavir (USAN); Brecanavir [USAN]; GW0385; GW640385
Molecular Formula: C33H41N3O10S2   Molecular Weight: 703.82274   InChIKey: JORVRJNILJXMMG-OLNQLETPSA-N
Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.   From: DrugBank
Show subcontent titlesTable of Contents
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Biomolecular Interactions and Pathways
Biological Test Results
Chemical and Physical Properties
_ _